StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CNTB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $2.42 | $2.38 | -1.65% | 0.1M |
| 05-18 | $2.39 | $2.38 | -0.42% | 0.1M |
| 05-19 | $2.34 | $2.19 | -6.41% | 0.1M |
| 05-20 | $2.21 | $2.31 | +4.52% | 0.2M |
| 05-21 | $2.36 | $2.36 | +0.00% | 0.1M |
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $169.00K | $64.00K | $64.00K | $48.00K |
Operating Income | $-19.61M | $-58.07M | $-42.55M | $-24.87M |
Net Income | $-19.40M | $-55.48M | $-40.37M | $-12.90M |
EPS (Diluted) | $-0.34 | $-1.00 | $-0.73 | $-0.42 |
Total Assets | $60.07M | $56.08M | $67.36M | $82.72M |
Total Liabilities | $17.44M | $14.10M | $11.99M | $11.38M |
Cash & Equivalents | $46.03M | $38.34M | $37.84M | $40.63M |
Free Cash Flow OCF − CapEx | $-16.00M | $-51.64M | $-40.37M | $-22.93M |
Shares Outstanding | 62.71M | 56.44M | 55.79M | 55.58M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.